Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24384347 | 0.77 | P2RY4 (0.38) | CNR1CNR2ALOX5PDK2ELANE | |
| SCHEMBL28136231 | 0.74 | MAPT (0.39) | CNR1CNR2ALOX5 | |
| SCHEMBL18242210 | 0.73 | MAPK1 (0.49) | ELANECTSGP2RY4 | |
| SCHEMBL30355267 | 0.73 | PDK2 (0.33) | CNR1CNR2ALOX5PDK2 | |
| SCHEMBL2281008 | 0.73 | PDK2 (0.33) | CNR1CNR2ALOX5PDK2 | |
| SCHEMBL18869450 | 0.72 | HEXA (0.40) | ELANECTSG | |
| SCHEMBL15655986 | 0.71 | ELANE (0.36) | PDK2ELANECTSG | |
| SCHEMBL15748685 | 0.71 | GABRA1 (0.42) | ELANECTSGGABRA1GABRB2 | |
| SCHEMBL18614444 | 0.71 | GPR3 (0.31) | — | |
| SCHEMBL940845 | 0.71 | TAAR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156544-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ELZEIN ELFATIH | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156544-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ADORA1, ADORA2A, ADORA3 | CNR1 75/4885CNR2 469/4885ALOX5 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.